Vertex Pharmaceuticals ( VRTX 2.53%) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs ...
Self-healing asphalt roads, made from biomass waste and designed with the help of artificial intelligence (AI), could offer a ...
Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming the healthcare ...
One sickle cell patient told ITV News the new gene therapy being rolled out for use on the NHS means they "finally have something to look towards". | ITV National News ...
Analyst Salveen Richter of Goldman Sachs maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), reducing the price target ...
Self-healing roads, made from biomass waste and designed using AI, could offer a solution to the country’s £143 million ...
The U.S. Food and Drug Administration (FDA) approved suzetrigine under the brand name Journavx on Jan. 30, 2025. Journavx is a first-in-class non-opioid painkiller that acts on sodium channels in the ...
A gene-editing therapy for sickle cell disease, with a price tag of £1.65m, is to be offered to patients on the NHS in ...
The gene-editing treatment will be available to certain patients with sickle cell disease in England as Vertex commits to collecting additional data.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
FDA approves new type of non-opioid pain medication in two decades - The new drug will be many times more expensive than a standard opioid option ...